Latest Tenofovir Stories
CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention.
In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than those who received a placebo pill (95% CI 15.4 to 62.6%; P=0.005).
NIH's NIAID-sponsored Study Finds Pre-exposure Prophylaxis Concept Effective Among Men who Have Sex with Men A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial published online Nov. 23 by the New England Journal of Medicine. The study, titled "Chemoprophylaxis...
The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.
In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.
Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today.
JOHANNESBURG and WASHINGTON, Nov.
NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2010 /PRNewswire/ -- Scientists from Chimerix, Inc.
BURLINGTON, Mass., Oct.
Higher clinical drop-out rates among women are a concern when testing for effectiveness of HIV treatments.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).